If there are multiple products targeting the same indication...

If there are multiple products targeting the same indication then clinicians have to make a choice. Clinicians tend to be conservative and lean towards what they are familiar with (this is where the first-in-class advantage come from), but over time the best-in-class tends to win market share.

The EAP requests suggest that what CU6 has is better than anything on the market. The data we have seen so far is also supports this. Combined with the production advantages of copper then this should be compelling to Big Pharma. Of course there is lots of risk, but everything is pointing in the right direction.